CTC Alternative Strategies’s AbbVie ABBV Stock Holding History

CTC Alternative Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.87M	Buy	+11,400	New	+$2.45M	4.14%	5
2025 Q2	–	Sell	-4,620	Closed	-$968K	–	145
2025 Q1	$968K	Buy	+4,620	New	+$898K	1.18%	19
2024 Q3	–	Sell	-14,000	Closed	-$2.4M	–	60
2024 Q2	$2.4M	Buy	+14,000	New	+$2.32M	1.02%	15
2023 Q3	–	Sell	-6,900	Closed	-$930K	–	74
2023 Q2	$930K	Buy	+6,900	New	+$1.01M	1.16%	13
2015 Q3	$348K	Buy	+6,400	New	+$417K	0.82%	23

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CTC Alternative Strategies's ABBV Position: Q2 2026 in Review

CTC Alternative Strategies opened a new position in AbbVie (ABBV) in Q2 2026: 11,400 shares worth $2.87M. The stake represents 4.14% of the portfolio and ranks #5 among its holdings. This is a return to the name: CTC Alternative Strategies previously reported a position in ABBV as recently as Q1 2025.

CTC Alternative Strategies first reported a position in ABBV in Q3 2015 and has held it in 5 quarters since. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

CTC Alternative Strategies held 11,400 shares of AbbVie worth $2.87M as of Q2 2026.
AbbVie was a new CTC Alternative Strategies position in Q2 2026.
AbbVie made up 4.14% of CTC Alternative Strategies's portfolio in Q2 2026, its #5 holding.
CTC Alternative Strategies first reported a position in AbbVie in Q3 2015 and has held it in 5 quarters since.
4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on CTC Alternative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.